HRP20120441T1 - Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a - Google Patents
Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a Download PDFInfo
- Publication number
- HRP20120441T1 HRP20120441T1 HRP20120441AT HRP20120441T HRP20120441T1 HR P20120441 T1 HRP20120441 T1 HR P20120441T1 HR P20120441A T HRP20120441A T HR P20120441AT HR P20120441 T HRP20120441 T HR P20120441T HR P20120441 T1 HRP20120441 T1 HR P20120441T1
- Authority
- HR
- Croatia
- Prior art keywords
- mixture
- amount
- weight
- hpmc
- mixture according
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 22
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 239000002532 enzyme inhibitor Substances 0.000 claims abstract 3
- 208000030507 AIDS Diseases 0.000 claims 4
- 230000000840 anti-viral effect Effects 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 229940126154 HIV entry inhibitor Drugs 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- -1 phosphate ester Chemical class 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- SWMDAPWAQQTBOG-UHFFFAOYSA-N fostemsavir Chemical compound C1=2N(COP(O)(O)=O)C=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 SWMDAPWAQQTBOG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/062—Organo-phosphoranes without P-C bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9413108P | 2008-09-04 | 2008-09-04 | |
PCT/US2009/055820 WO2010028108A2 (en) | 2008-09-04 | 2009-09-03 | Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120441T1 true HRP20120441T1 (hr) | 2012-06-30 |
Family
ID=41726353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120441AT HRP20120441T1 (hr) | 2008-09-04 | 2012-05-23 | Stabilna farmaceutska smjesa za optimiziranu dopremu inhibitora prianjanja hiv-a |
Country Status (16)
Country | Link |
---|---|
US (2) | US20100056540A1 (sl) |
EP (1) | EP2323633B1 (sl) |
JP (1) | JP5638527B2 (sl) |
CN (1) | CN102143739B (sl) |
AT (1) | ATE550016T1 (sl) |
CA (1) | CA2735008C (sl) |
CY (1) | CY1112816T1 (sl) |
DK (1) | DK2323633T3 (sl) |
ES (1) | ES2383149T3 (sl) |
HR (1) | HRP20120441T1 (sl) |
NL (1) | NL301118I2 (sl) |
PL (1) | PL2323633T3 (sl) |
PT (1) | PT2323633E (sl) |
SI (1) | SI2323633T1 (sl) |
SM (1) | SMT201200029B (sl) |
WO (1) | WO2010028108A2 (sl) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9248139B2 (en) * | 2011-12-21 | 2016-02-02 | Bristol-Myers Squibb Company | Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023265A (en) * | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
US5124327A (en) * | 1991-09-06 | 1992-06-23 | Merck & Co., Inc. | HIV reverse transcriptase |
JP2686215B2 (ja) * | 1993-04-28 | 1997-12-08 | 信越化学工業株式会社 | 徐放性錠剤 |
US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
CA2173818A1 (fr) * | 1996-04-10 | 1997-10-11 | Francois Chouinard | Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose |
US20020061892A1 (en) * | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
US6476034B2 (en) * | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
US6825201B2 (en) * | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
US20040063744A1 (en) * | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
US20060167044A1 (en) * | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
US7601715B2 (en) * | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
-
2009
- 2009-09-03 SI SI200930268T patent/SI2323633T1/sl unknown
- 2009-09-03 WO PCT/US2009/055820 patent/WO2010028108A2/en active Application Filing
- 2009-09-03 AT AT09792207T patent/ATE550016T1/de active
- 2009-09-03 PL PL09792207T patent/PL2323633T3/pl unknown
- 2009-09-03 JP JP2011526181A patent/JP5638527B2/ja active Active
- 2009-09-03 US US12/553,310 patent/US20100056540A1/en not_active Abandoned
- 2009-09-03 ES ES09792207T patent/ES2383149T3/es active Active
- 2009-09-03 DK DK09792207.4T patent/DK2323633T3/da active
- 2009-09-03 EP EP09792207A patent/EP2323633B1/en active Active
- 2009-09-03 PT PT09792207T patent/PT2323633E/pt unknown
- 2009-09-03 CA CA2735008A patent/CA2735008C/en not_active Expired - Fee Related
- 2009-09-03 CN CN200980135118.2A patent/CN102143739B/zh not_active Expired - Fee Related
-
2012
- 2012-05-23 HR HRP20120441AT patent/HRP20120441T1/hr unknown
- 2012-06-01 CY CY20121100500T patent/CY1112816T1/el unknown
- 2012-06-19 SM SM201200029T patent/SMT201200029B/xx unknown
-
2014
- 2014-12-11 US US14/567,554 patent/US20150158891A1/en not_active Abandoned
-
2021
- 2021-07-26 NL NL301118C patent/NL301118I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
JP2012502042A (ja) | 2012-01-26 |
ATE550016T1 (de) | 2012-04-15 |
CN102143739A (zh) | 2011-08-03 |
NL301118I2 (nl) | 2022-02-22 |
ES2383149T3 (es) | 2012-06-18 |
PT2323633E (pt) | 2012-05-29 |
NL301118I1 (sl) | 2021-07-23 |
SMT201200029B (it) | 2012-09-07 |
CY1112816T1 (el) | 2016-02-10 |
EP2323633B1 (en) | 2012-03-21 |
DK2323633T3 (da) | 2012-07-09 |
WO2010028108A2 (en) | 2010-03-11 |
JP5638527B2 (ja) | 2014-12-10 |
CA2735008A1 (en) | 2010-03-11 |
EP2323633A2 (en) | 2011-05-25 |
WO2010028108A3 (en) | 2010-09-02 |
US20150158891A1 (en) | 2015-06-11 |
PL2323633T3 (pl) | 2012-08-31 |
SI2323633T1 (sl) | 2012-07-31 |
CN102143739B (zh) | 2014-12-17 |
CA2735008C (en) | 2016-11-29 |
US20100056540A1 (en) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Andrei et al. | Cidofovir activity against poxvirus infections | |
SG11201908101YA (en) | Hepatitis b virus surface antigen inhibitor | |
MA32385B1 (fr) | Forme posologique pharmaceutique en capsule comprenant une formulation en suspension d'un derive d'indolinone | |
MA34013B1 (fr) | Inhibiteurs du virus de l'hépatite c | |
UA103844C2 (ru) | Фармацевтический состав, который содержит в матрице, которая подвергается эрозии, один или более эфиров фумаровой кислоты | |
HRP20192026T1 (hr) | Formulacija tableta od neratinib maleata | |
BRPI0613499A8 (pt) | formulação de comprimido farmacêutico de 1[(3-hidróxi-adamant-1-ilamino)-acetil]- pirrolidino-2(s)-carbonitrila de liberação modificada, comprimido em multicamada, comprimido farmacêutico e cápsula contendo a mesma, processo de produção da mesma, seu uso, processo de preparação de comprimido bem como forma de dosagem farmacêutica | |
RU2013121788A (ru) | Ингибиторы репликации вич | |
SI2529622T1 (sl) | Inhibitorji Bruton tirozin kinaze | |
EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
MY160130A (en) | Hepatitis c virus inhibitors | |
JP2010511596A5 (sl) | ||
RS20070511A (en) | Modified release pharmaceutical compositions and processes thereof | |
AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
DK2041133T3 (da) | Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik | |
BR0209320A (pt) | ésteres de uridina farmaceuticamente ativos | |
Krečmerová et al. | Phosphonates and phosphonate prodrugs in medicinal chemistry: Past successes and future prospects | |
BR112012009857A8 (pt) | Composições farmacêuticas sólidas contendo um inibidor de integrase | |
JP2018527305A5 (sl) | ||
NZ599762A (en) | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea | |
RU2012109614A (ru) | Фармацевтические композиции, содержащие производные бисфосфоната и высокие дозы холекальциферола | |
SI2800558T1 (sl) | Stabilna farmacevtska formulacija za oralno uporabo, ki vsebuje levocetirizine ali njihovo farmacevtsko sprejemljivo sol, in montelukast ali njegovo farmacevtsko sprejemljivo sol | |
JP2011502131A5 (sl) | ||
HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin | |
RU2008136315A (ru) | Композиции ситаксентана натрия |